Multi-tracer and multiparametric PET imaging to detect the IDH mutation in glioma: a preclinical translational in vitro, in vivo, and ex vivo study.
Gliomas
IDH mutation
PET
[18F]DPA-714
Journal
Cancer imaging : the official publication of the International Cancer Imaging Society
ISSN: 1470-7330
Titre abrégé: Cancer Imaging
Pays: England
ID NLM: 101172931
Informations de publication
Date de publication:
18 Mar 2022
18 Mar 2022
Historique:
received:
02
11
2021
accepted:
03
03
2022
entrez:
19
3
2022
pubmed:
20
3
2022
medline:
23
3
2022
Statut:
epublish
Résumé
This translational study explores multi-tracer PET imaging for the non-invasive detection of the IDH1 mutation which is a positive prognostic factor in glioma. U87 human high-grade glioma (HGG) isogenic cell lines with or without the IDH1 mutation (CRISP/Cas9 method) were stereotactically grafted into rat brains, and examined, in vitro, in vivo and ex vivo. PET imaging sessions, with radiotracers specific for glycolytic metabolism ([ In vitro, IDH1+ cells (i.e. cells expressing the IDH1 mutation) showed lower levels of [ [18F]DPA-714 and [18F] FDopa both correlate with the presence of the IDH1 mutation in HGG. These radiotracers are therefore good candidates for translational studies investigating their clinical applications in patients.
Sections du résumé
BACKGROUND
BACKGROUND
This translational study explores multi-tracer PET imaging for the non-invasive detection of the IDH1 mutation which is a positive prognostic factor in glioma.
METHODS
METHODS
U87 human high-grade glioma (HGG) isogenic cell lines with or without the IDH1 mutation (CRISP/Cas9 method) were stereotactically grafted into rat brains, and examined, in vitro, in vivo and ex vivo. PET imaging sessions, with radiotracers specific for glycolytic metabolism ([
RESULTS
RESULTS
In vitro, IDH1+ cells (i.e. cells expressing the IDH1 mutation) showed lower levels of [
CONCLUSIONS
CONCLUSIONS
[18F]DPA-714 and [18F] FDopa both correlate with the presence of the IDH1 mutation in HGG. These radiotracers are therefore good candidates for translational studies investigating their clinical applications in patients.
Identifiants
pubmed: 35303961
doi: 10.1186/s40644-022-00454-6
pii: 10.1186/s40644-022-00454-6
pmc: PMC8932106
doi:
Substances chimiques
Receptors, GABA
0
TSPO protein, human
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Informations de copyright
© 2022. The Author(s).
Références
J Nucl Med. 2007 Sep;48(9):1468-81
pubmed: 17704239
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5
pubmed: 21289278
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1381-1390
pubmed: 31529264
Nat Commun. 2021 Jan 27;12(1):614
pubmed: 33504762
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Mar;32(3):360-3
pubmed: 26927556
Cancer Res. 2018 May 1;78(9):2290-2304
pubmed: 29358170
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2581-2589
pubmed: 31410540
Cancer Sci. 2012 Feb;103(2):269-73
pubmed: 22034964
Front Oncol. 2021 Oct 05;11:735257
pubmed: 34676168
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1368-1380
pubmed: 31486876
Cancer Res. 1995 Jun 15;55(12):2691-5
pubmed: 7780986
PLoS One. 2015 Feb 23;10(2):e0118781
pubmed: 25706986
Magn Reson Med. 2020 Sep;84(3):1152-1160
pubmed: 32003035
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4129-4132
pubmed: 34518904
Nat Commun. 2013;4:2429
pubmed: 24019001
Zhonghua Yi Xue Za Zhi. 2019 Oct 22;99(39):3105-3109
pubmed: 31648456
Mol Imaging Biol. 2019 Feb;21(1):113-121
pubmed: 29869061
NMR Biomed. 2021 Jun;34(6):e4490
pubmed: 33599048
Clin Cancer Res. 2012 Oct 15;18(20):5562-71
pubmed: 23071358
Bioorg Med Chem Lett. 2018 Feb 15;28(4):694-699
pubmed: 29366652
J Nucl Med. 2022 Jan;63(1):147-157
pubmed: 34016731
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557
pubmed: 30519867
ACS Med Chem Lett. 2018 May 01;9(7):606-611
pubmed: 30034587
Nature. 2010 Jun 17;465(7300):966
pubmed: 20559394
J Neurooncol. 2012 Mar;107(1):197-205
pubmed: 22015945
J Neurooncol. 2019 Dec;145(3):441-447
pubmed: 31667733
Clin Transl Imaging. 2016;4:145-156
pubmed: 27077069
Appl Radiat Isot. 2012 Mar;70(3):489-97
pubmed: 22104496
J Nucl Med. 2016 Oct;57(10):1543-1547
pubmed: 27261521
Nucl Med Biol. 2013 Aug;40(6):831-40
pubmed: 23915802
Tumour Biol. 2015 Feb;36(2):655-62
pubmed: 25283382
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
IEEE Trans Med Imaging. 1994;13(4):716-24
pubmed: 18218550
Neuro Oncol. 2012 Dec;14(12):1465-72
pubmed: 23090985
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Ann Neurol. 2011 Mar;69(3):455-63
pubmed: 21446021
J Neurooncol. 2007 Jan;81(1):1-7
pubmed: 16868661
Brain Tumor Pathol. 2016 Jul;33(3):161-8
pubmed: 27295313
Q J Nucl Med Mol Imaging. 2018 Sep;62(3):254-266
pubmed: 29696948
Neuro Oncol. 2014 Mar;16(3):414-20
pubmed: 24305712
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):580-590
pubmed: 30244386
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):321-331
pubmed: 27550420
Radiat Oncol. 2019 May 30;14(1):89
pubmed: 31146757
Neuro Oncol. 2016 Nov;18(11):1559-1568
pubmed: 27154922
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1408-1410
pubmed: 28451826
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Nature. 2012 Feb 15;483(7390):474-8
pubmed: 22343901
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):174-185
pubmed: 33721063
Cancer Res. 2016 Jan 1;76(1):43-9
pubmed: 26669865